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Abstract
Background: Lung cancer patients with KRAS mutation(s) have a poor prognosis due in part to the development
of resistance to currently available therapeutic interventions. Development of a new class of anticancer agents that
directly targets KRAS may provide a more attractive option for the treatment of KRAS-mutant lung cancer.
Results: Here we identified a small molecule KRAS agonist, KRA-533, that binds the GTP/GDP-binding pocket of
KRAS. In vitro GDP/GTP exchange assay reveals that KRA-533 activates KRAS by preventing the cleavage of GTP into
GDP, leading to the accumulation of GTP-KRAS, an active form of KRAS. Treatment of human lung cancer cells with
KRA-533 resulted in increased KRAS activity and suppression of cell growth. Lung cancer cell lines with KRAS
mutation were relatively more sensitive to KRA-533 than cell lines without KRAS mutation. Mutating one of the
hydrogen-bonds among the KRA-533 binding amino acids in KRAS (mutant K117A) resulted in failure of KRAS to
bind KRA-533. KRA-533 had no effect on the activity of K117A mutant KRAS, suggesting that KRA-533 binding to
K117 is required for KRA-533 to enhance KRAS activity. Intriguingly, KRA-533-mediated KRAS activation not only
promoted apoptosis but also autophagic cell death. In mutant KRAS lung cancer xenografts and genetically
engineered mutant KRAS-driven lung cancer models, KRA-533 suppressed malignant growth without significant
toxicity to normal tissues.
Conclusions: The development of this KRAS agonist as a new class of anticancer drug offers a potentially effective
strategy for the treatment of lung cancer with KRAS mutation and/or mutant KRAS-driven lung cancer.
Keywords: KRAS, Agonist, Apoptosis, Autophagy, NSCLC, Therapy

Background
RAS family genes, including HRAS, KRAS and NRAS, are
the most common oncogenes in human cancer, and
encode extremely similar proteins made up of chains of
188 to 189 amino acids. The sequences and structural features of these three proteins are highly conserved, except
for their carboxyl-terminal domains and post-translational
lipid modifications [1, 2]. HRAS, KRAS and NRAS are
regulated in a similar manner within the cell. The RAS
genes encode monomeric GTPases that function as molecular switches in signal transduction pathways regulating
cell proliferation, differentiation and survival in mammalian cells [1]. Mutations that can constitutively activate
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RAS have been found in 20% ~ 25% of all human cancers
[3]. KRAS has the highest mutation rate compared to
HRAS and NRAS in various types of cancers [4, 5]. KRAS
is a proto-oncogene and its gene product was first found
as a p21 GTPase. KRAS binds to GTP in its active state
and possesses an intrinsic enzymatic activity which cleaves
the terminal phosphate of the nucleotide, converting it to
GDP. Upon conversion of GTP to GDP, KRAS is deactivated. The rate of conversion is usually slow, but can be
increased dramatically by an accessory GTPase-activating
protein (GAP) [4]. In turn, KRAS can bind to guanine nucleotide exchange factors (GEFs) (such as SOS), which
force the release of bound nucleotide (GDP). GTP binding
enables several residues, primarily in the switch I region
(residues 30–40) and switch II region (residues 60–70), to
adopt a conformation that permits KRAS effector proteins
to bind; these switches are regulated by GAPs and GEFs
[6, 7]. In mammalian cells, endogenous KRAS proteins
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are predominantly in the GDP state and activation is transient [8]. However, the common oncogenic mutations in
KRAS proteins interfere with GTP hydrolysis, resulting in
proteins that remain in the active GTP state and continue
to transmit signals to effector pathways [1]. Thus, KRAS
acts as a molecular on/off switch. Once it is turned on, it
recruits and activates proteins necessary for the propagation of signaling of growth factors and other receptors,
such as c-Raf and PI3K [9–12].
Somatic KRAS mutations are found at high rates in
leukemia [13, 14], colorectal cancer [15], pancreatic cancer
[16] and non-small cell lung cancer (NSCLC) [17]. In
NSCLC, KRAS mutation is observed in up to 30–40% of
cases [11, 12, 18]. The most common KRAS mutations include G12C, G12D, G12R, G12S, G12 V, G13D and Q61H
[19, 20]. Beyond the most common hotspot alleles in exons
2 and 3, mutations in exon 4 of KRAS, including K117 N
and A146T, have also been found in patients with colorectal
cancer [21, 22]. KRAS mutations constitutively activate
KRAS and subsequently its downstream Raf/MEK/ERK1/2
and PI3K/PIP3/AKT survival pathways in various cancers,
including lung cancer [9–12]. However, over the past two
decades, evidence has gradually accumulated to support a
paradoxical role for RAS proteins in the initiation of cell
death pathways [1, 23–25]. Hyperactive RAS forces cells
into the pathway of programmed cell death [26]. Vitamin C
treatment selectively kills mutant KRAS expressing tumor
cells, but not wild-type KRAS containing cells [27]. Interestingly, either glucose withdrawal or glucose-mediated hyperactivation of RAS is able to trigger apoptosis [26, 28].
RAS oncogenes trigger apoptosis only under specific conditions [26]. Thus, manipulation of the opposing functions of
KRAS in cell proliferation/survival versus cell death should
be an attractive approach to develop new strategies for the
treatment of various types of cancers, especially those with
mutant KRAS. Currently, there are no effective targeted
therapies for patients with KRAS mutant cancers [29, 30].
KRAS has been considered an “undruggable” target and it
is difficult to inhibit its intracellular activity [5, 31] for the
following reasons [31]: first, whether KRAS adopts an active
or inactive form depends on its GTP or GDP binding status
rather than it being a substrate of catalytic reactions; second, there is a picomolar affinity between KRAS and GTP
while micromolar concentrations of GTP exist in cancer
cells; third, KRAS lacks a sufficiently large and deep hydrophobic pocket for small molecule binding, aside from the
challenging nucleotide-binding site [4–6, 32]. Therefore,
numerous efforts made by industry and academic laboratories have failed to design a drug to inhibit KRAS activity
in cancer cells by directly targeting KRAS. Since intracellular KRAS activity is difficult to disrupt, and activated KRAS
has been demonstrated to trigger death pathways [1], changing the nature of KRAS signaling from pro-survival to
pro-death by directly targeting KRAS in cancer cells may

Page 2 of 16

represent an entirely new strategy for cancer therapy. Here
we identified KRA-533 as a novel KRAS agonist that binds
to the GTP/GDP binding pocket in the KRAS protein to
prevent GTP cleavage, resulting in the accumulation of
constitutively active GTP-bound KRAS that triggers both
apoptotic and autophagic cell death pathways in cancer
cells, leading to potent suppression of mutant KRAS lung
cancer in vitro and in animal models.

Methods
Materials

Small molecule NSC112533 (KRA-533) was obtained from
the Drug Synthesis and Chemistry Branch, Developmental
Therapeutic Program, Division of Cancer Treatment and
Diagnosis, National Cancer Institute (NCI, Bethesda, MD;
http://dtp.nci.nih.gov/RequestCompounds). KRAS was
purchased from Thermo Fisher Scientific (Rockford, IL).
Anti-GFP, PARP and Beclin-1 antibodies, and KRAS
shRNA (sc-35,731-SH) were purchased from Santa Cruz
Biotechnology (Santa Cruz, CA). ERK, p-ERK (Thr202/
Tyr204), LC3I/II and active/cleaved caspase-3 antibodies
were purchased from Cell Signaling Technology (Danvers,
MA). Protein Thermal Shift™ Dye Kit and Raf-1-RBD beads
for pull-down of active RAS and Detection Kit were
purchased from Thermo Fisher Scientific (Rockford, IL).
Purified recombinant RASA1 and RASGRP1 proteins
were purchased from OriGene Technologies (Rockville,
MD). [γ-35S] GTP was purchased from PerkinElmer (Waltham, MA). Oligonucleotides were purchased from Integrated DNA Technologies (Coralville, IA). Chloroquines,
3-methyladenine (3-MA) and JC-1 were purchased from
MedChemExpress (Monmouth Junction, NJ). All other
reagents used were obtained from commercial sources
unless otherwise stated.
Cell lines and cell culture

Normal lung epithelial and lung cancer cell lines were obtained from the American Type Culture Collection. NSCLC
cell line A549 was cultured in Dulbeccos’ Modified Eagles’
Medium (DMEM)/F-12medium supplemented with 10%
FBS as described [33]. HCC827, H292, H1975, H322,
Calu-1, H157, H358 and H1792 were cultured in RPMI1640 medium supplemented with 5% FBS and 5% BS.
These cell lines were used for the described experiments
without further authentication.
Protein analysis by Western blot

Cells were lysed with EBC buffer at 4 °C for 30 min.
After sonication, samples were centrifuged at 12000×g
for 15 min, and supernatant was quantified using a BCA
protein assay kit (Thermo Fisher Scientific, Rockford,
IL). Equal amounts of protein samples were separated by
SDS-PAGE, and transferred to nitrocellulose membranes
using an electro-blotting apparatus (Bio-Rad, Hercules,
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CA, USA). The membranes were blocked in blocking
buffer (PBS-T plus 5% skimmed milk), and incubated
with primary antibodies overnight at 4 °C. The membranes were washed with PBS-T and incubated with
horseradish peroxidase-conjugated secondary antibodies
for 0.5 h at room temperature. Protein expression was
visualized using the ECL kit (Amersham Biosciences) as
described [34].
Plasmids and transfections

GFP-LC3 plasmid was kindly provided by Dr. William A.
Dunn (University of Florida). Human KRAS-WT, G12C,
G12D and G13D cDNA (s) in pEGFP-C3 expression plasmids were provided by Dr. Wei Zhou (Emory University,
USA). For generation of single KRAS point mutations at
codons 17 (S to A) and 117 (K to A), primers were synthesized as follows: S17A, Forward: 5′-CTG GTG GCG TAG
GCA AGG CT GCC TTG ACG ATA CAG-3′, Reverse:
5′-CTG TAT CGT CAA GGC AGC CTT GCC TAC
GCC ACC AG-3′; K117A, Forward: 5′-CCT ATG GTC C
TA GTA GGA AAT GCA TGT GAT TTG CCT TCC
AGA AC-3′, Reverse: 5′-GTT CTG GAA GGC AAA TCA
CAT GCA TTT CCT ACT AGG ACC ATA GG-3′. These
KRAS single point mutations were created using the QuikChange™ Site-Directed Mutagenesis Kit (Agilent Technologies, CA) according to the manufacturer’s instructions [35].
Each single mutant was confirmed by sequencing of the
cDNA. KRAS mutants were transfected into cells using Lipofectamine 2000 (Invitrogen) according to the manufacturer’s instructions.
Measurement of intracellular KRAS activity

The cellular activity of the KRAS protein was measured
using active RAS pull-down and detection kit according
to the manufacturer’s instructions (Thermo Fisher Scientific, Rockford, IL) as described [36, 37]. GTP-bound
forms of KRAS were pulled-down from cell lysates using
GST-Raf-1 RBD beads. After washing, loading buffer
was added to samples and boiled for 5 min, followed by
SDS-PAGE and Western blot using KRAS antibody.
Production of purified KRAS protein

WT, G12C, G12D, G13D, S17A or K117A KRAS mutant
cDNA were cut from pEGFP-C3 constructs with BamH
I and Hind III, and cloned into pET-20b (+) vector
(His-tag) (GE Healthcare) between BamH I and Hind
III. The recombinant KRAS proteins were expressed in
Escherichia coli (BL21 (DE3)) and purified as described
[38]. Briefly, after bacterial growth to an absorbance
(OD) at 600 nm of 0.4–0.6 in Terrific Broth containing
30 mg/L kanamycin at 37 °C, induction was carried out
at 18 °C using 0.5 mM isopropyl-b-D-thiogalactoside
(IPTG), and growth was continued at 18 °C for about 18
h. The bacteria were collected by centrifugation, and the

Page 3 of 16

obtained pellet either stored at − 80 °C or used freshly
for the subsequent steps. His-tagged-KRAS was purified
using 5-ml Hi Trap Ni2 + −Sepharose column equilibrated with buffer A containing 20 mM imidazole.
Bound proteins were eluted with a linear concentration
gradient of imidazole (i.e. 50 and 350 mM) in 50 ml buffer A. Fractions containing KRAS protein were pooled,
dialyzed against buffer B (20mMTris-HCl, pH 8.0, 100
mM NaCl, 10% (v/v) glycerol and 1 mM DTT) and
loaded onto a 1-ml Hi Trap Q Sepharose FF column.
Bound proteins were eluted with a linear concentration
gradient of NaCl (i.e. 50 and 500 mM) in 12 ml buffer B.
Purified proteins were stored at − 80 °C. The concentration of purified proteins was determined by Bradford
assay. The values obtained by Bradford assay were divided by the predicted molecular mass of the appropriate protein to calculate its molar concentration.
GDP-GTP exchange assay in cell-free system

In vitro GDP-GTP exchange assay was performed as described [39]. Briefly, purified WT or mutant KRAS proteins (600 nM) were incubated with purified GEF
(RASGRP1, 180 nM each) and GAP (RASA1, 180 nM
each) proteins in buffer B [50 mM Tris·HCl (pH 7.4), 50
mM NaCl, 5 mM MgCl2, 1 mM DTT, and 20 mM imidazole] containing [γ-35S]-GTP (11 μM) in the absence or
presence of increasing concentrations of KRA-533 at 25
°C for 60 min. After intensively washing, KRAS activity
was quantified by liquid scintillation counting.
Measurement of KRA-533/KRAS binding by thermal shift
assay

Thermal shift assay was performed using the Protein Thermal Shift Dye Kit (Thermo Fisher Scientific, Rockford, IL)
as described [40]. Purified WT and KRAS mutant proteins
were incubated with increasing concentrations of KRA-533
in Protein Thermal Shift buffer containing Thermal Shift
Dye at room temperature, followed by measurement of the
fluorescence release using Real-Time PCR Systems
(Applied Biosystems). Data were analyzed using Protein
Thermal Shift Software v1.0 (Life Technologies) [40].
Clonogenic survival assay

Cells were seeded in 6-well plates or cell culture dishes.
After 12 h, cells were treated with KRA-533 (10 μM).
The medium was replaced with fresh medium containing KRA-533 every 3 days. After 10 days of treatment,
the medium was removed and cell colonies were stained
with crystal violet (0.1% in 20% methanol). Surviving
colonies were counted and the surviving fraction (SF)
was calculated using the formula SF = treatment colony
numbers/control colony numbers after at least three
independent experiments as described [41].
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Silencing of KRAS

Human KRAS shRNA and Ctrl shRNA in pRS shRNA vectors were obtained from Santa Cruz Biotechnology (Santa
Cruz, CA). Human KRAS shRNA Plasmid is a pool of 3
target-specific lentiviral vector plasmids each encoding 19–
25 nt (plus hairpin) shRNAs designed to specifically knock
down KRAS gene expression. Sc-35,731-SHA: hairpin
sequence, 5′ GAT CCG GAA GCA AGT AGT AAT TGA
TTC AAG AGA TCA ATT ACT ACT TGC TTC CTT T
TT 3′; sc-35,731-SHB: hairpin sequence: 5′ GAT CCC T
AG AAC AGT AGA CAC AAA TTC AAG AGA TTT G
TG TCT ACT GTT CTA GTT TTT 3′, sc-35,731-SHC:
hairpin sequence, 5′ GAT CCG AAC CTT TGA GCT
TTC ATA TTC AAG AGA TAT GAA AGC TCA AAG
GTT CTT TTT 3′. For pseudovirus production, KRAS
shRNA plasmids were cotransfected into 293FT cells with a
retrovirus packaging plasmid mixture (Agilent technologies,
CA) using the Nanojuice transfection kit (EMD Chemical,
Inc.). After 48 h, the virus-containing media were harvested
by centrifugation at 20,000×g. Human lung cancer A549
cells were infected with virus-containing media in the presence of polybrene (8 μg/ml) for 24 h. Stable positive clones
were selected using 1 μg/ml puromycin. The silencing efficiency of the targeted KRAS gene was confirmed by Western blotting.
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Kit from Abcam (Cambridge, MA) according to the
manufacturer’s instructions. OD values were analyzed by
measuring the absorbance at 400–405 nm with microplate reader (Perkin-Elmer, Waltham, MA, USA).
Lung cancer xenografts and treatments

Six-week-old female Nu/Nu nude mice were purchased
from Harlan and housed under pathogen-free conditions
in micro isolator cages. All animal treatments were
undertaken in accordance with protocols approved by
the Institutional Animal Care and Use Committee
(IACUC) at Emory University (Atlanta, GA). 3 × 106
A549 cells in Hanks’ Balanced Salt Solution (HBSS,
Gibco) were injected into subcutaneous tissue at the
flank region of nude mice. The tumors were allowed to
grow to an average volume of about 250 mm3 before initiation of therapy as described [45]. Mice were treated
with KRA-533 intraperitoneally (i.p.). During treatment,
tumor volume (V) was measured by caliper measurements once every 2 days and calculated with the formula: V ¼ (L× W2)/2 (L is the length and W is the
width). Mice were sacrificed by inhaled CO2 at the end
of treatment. Harvested tumors were weighed and immediately fixed in formalin for immunohistochemistry.
Immunohistochemistry (IHC) analysis

Apoptosis assay

Apoptotic and viable cells were detected using an Annexin
V/PI kit (BD Pharmingen, CA) according to the manufacturer’s instructions. The percentage of viable cells or
apoptotic cells was determined by fluorescence-activated
cell sorter (FACS) analysis as described [42, 43].
Cell proliferation assay

NSCLC cells were seeded in 96-well plates at 6 × 103
cells per well and allowed to grow overnight. Then, cells
were treated with KRA533, followed by analysis of cell
proliferation using MTS Cell Proliferation Colorimetric
Assay Kit from Promega (Madison, WI) according to the
manufacturer’s instructions. The optical density (OD)
values were analyzed by measuring the absorbance at
490–500 nm with microplate reader (Perkin-Elmer,
Waltham, MA, USA).
Measurement of autophagy with GFP-LC3 construct

GFP-LC3 constructs were transfected into human lung
cancer cells, followed by treatment with increasing concentrations of KRA-533 for 48 h. Autophagic cells were
visualized by Axioplan Zeiss microscope (Zeiss, German)
and quantified as described [44].
Caspase 3 activity assay

Cells were treated with KRA-533, followed by analysis of
caspase 3 activity using a Caspase 3 Colorimetric Assay

Tumors were harvested, fixed in formalin and embedded in
paraffin. Representative sections from paraffin-embedded
tumor tissues were analyzed by IHC staining using
anti-active caspase 3 (1:100), LC3-II (1:100) or pERK (1100)
antibodies. Active caspase 3-positive cells, LC3-II-positive
cells or pERK-positive cells in tumor tissues were scored at
400× magnification. The average number of positive cells
per 0.0625 mm2 area was determined from three separate
fields in each of three independent tumor samples as
described [45, 46].
Genetically engineered lox-stop-lox (LSL)-KRASG12D and
LSL-KRASG12D LKB1fl/fl (KL) mouse models, treatment and
tumor burden quantification

Lox-stop-lox (LSL)-KRASG12D and LSL-KRASG12D LKB1fl/
(KL) were generated as previously described [47, 48]. All
studies were performed on protocols approved by the
Emory University IACUC. After cre-adenovirus infection,
10 weeks for KRASG12D mice or 6 weeks for KL mice, mice
were treated with KRA-533 intraperitoneally (i.p) for 3
months (KRASG12D mice) or 8 weeks (KL mice). Mice were
euthanized with CO2 asphyxiation. After lung perfusion
with PBS, the left lung lobes were harvested from mice in
control and KRA-533 treated groups and immediately fixed
in 10% neutral buffered formalin (Fisher Scientific, Kalamazoo, MI), horizontally cut into three equal parts and
embedded in paraffin blocks. Three parts of lung tissues
representing different regions of the lung were vertically

fl
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put into paraffin blocks for hematoxylin-eosin (H&E) staining. Lung tissue samples were sectioned at 3 μm three times
for placement of slides and stained with H&E. H&E stained
samples were scanned using Nano Zoomer 2.0-HT (Hamamatsu, Japan) and images were analyzed using ImageScope
viewing software (Leica Biosystems, Buffalo Grove, IL).
Tumor numbers were counted under a microscope and
tumor area was quantified using Openlab modular imaging
software (PerkinElmer, Waltham, MA) as previously described [46, 48].
Mouse blood analysis

Whole blood (250 mL) was collected in EDTA-coated tubes
via cardiac puncture of anesthetized mice for hematology
studies. Specimens were analyzed for white blood cells
(WBC), red blood cells (RBC), platelets (PLT), alanine aminotransferase (ALT), aspartate aminotransferase (AST), and
blood urea nitrogen (BUN) in the Clinical Pathology Laboratory at the University of Georgia (Athens, GA).
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KRAS activity in most human lung cancer cell lines
tested, except H292. Intriguingly, KRA-533 enhanced
KRAS activity to a greater extent in cell lines bearing
KRAS mutation than in cell lines without KRAS mutation (Fig. 1B). Colony formation analysis following
10-day’s treatment revealed that human lung cancer cell
lines with KRAS mutation (i.e. A549, H358, H157,
Calu-1 and H1972) were relatively more sensitive to
KRA-533-mediated cell growth suppression than those
without KRAS mutation (i.e. H292, HCC827, H1975 and
H322) (Fig. 1C and D). Cell proliferation was also measured following treatment of cells for 48 h using MTS
Cell Proliferation Colorimetric Assay Kit. Treatment of
various NSCLC cells with KRA-533 resulted in suppression of cell proliferation. Similarly, A549, H157 and
Calu-1 cell lines bearing KRAS mutation were more sensitive to KRA-533 than H292 cells without KRAS mutation (Additional file 1: Figure S1). These findings suggest
that KRA-533 may be more suitable to treat mutant
KRAS lung cancer.

Statistical analysis

All data are presented as mean ± standard deviation (SD)
from at least three independent experiments. The statistical significance of differences between groups was analyzed with 2-tailed t test. We chose the sample size to
detect a minimum effect size of 1.5 with at least 80%
power and a type I error of 0.05 for each comparison. A
value of P < 0.05 was considered statistically significant.

Results
Screening of small molecules that target the GTP/GDP
binding pocket of KRAS

A library containing ~ 300,000 small molecules from the
National Cancer Institute (NCI) was employed to dock
the GTP/GDP binding pocket of KRAS (PDB ID code:
4EPT) using the University of California, San Francisco
(UCSF) DOCK 6.1 program suite as we previously described [49–51]. The small molecules were ranked according to their energy scores. Top 500 small molecules with
predicted binding energies were selected for screening of
cytotoxicity in human lung cancer cells by sulforhodamine
B (SRB) assay as previously described. Among these small
molecules, the compound NSC112533 (C13H16BrNO3,
molecular weight [MW] 314.17) had the most potent activity against human lung cancer cells. We named this lead
compound small-molecule KRAS agonist-533 (KRA-533).
The molecular modeling of KRA-533 in complex with
KRAS GTP/GDP binding pocket is shown in Fig. 1A.
To test whether KRA-533 regulates KRAS activity in
lung cancer cells, human lung cancer cell lines with or
without KRAS mutation were treated with KRA-533
(10 μM) for 48 h. GTP-KRAS (active form of KRAS) was
pulled down using Raf-1-RBD beads, followed by Western blot using KRAS antibody. KRA-533 enhanced

KRA-533 directly binds and activates WT and mutant
KRAS in an in vitro cell-free system

To test whether KRA-533 directly binds to KRAS, a
thermal shift assay was employed as described [40]. Dose
dependent increases in melting temperature (Tm) were
observed when purified KRAS WT, G12C, G12D and
G13D mutant proteins were incubated with increasing
concentrations of KRA-533 (Fig. 2A). These results indicate that KRA-533 can directly bind to WT, G12C,
G12D and G13D mutant KRAS proteins.
To further assess whether KRA-533 activates KRAS directly, an in vitro cell-free GDP-GTP exchange experiment
was carried out as described [39]. Purified WT, G12C,
G12D or G13D mutant KRAS proteins were incubated with
purified GEF (RASGRP1) and GAP (RASA1) proteins in reaction buffer containing [γ-35S]-GTP in the absence or presence of increasing concentrations of KRA-533 at 25 °C for
60 min. KRAS activity was quantified by liquid scintillation
counting. Mutant KRAS G12C, G12D and G13D displayed
greater KRAS activity than WT KRAS in the absence of
KRA-533 (Fig. 2B). Addition of KRA-533 activated WT
KRAS to increase its activity in a dose-dependent manner.
Intriguingly, KRA-533 further enhanced the activities of active KRAS mutants (i.e. G12C, G12D and G13D) (Fig. 2B).
These findings indicate that KRA-533 not only activates
WT KRAS but also has the capacity to further enhance
KRAS activity of mutant KRAS.
K117 is a required site for KRA-533 to bind and activate
KRAS

Our findings reveal that KRA-533 not only binds to but
also directly activates WT and most common KRAS mutants, including G12C, G12D and G13D. Structural
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Fig. 1 KRA-533 activates KRAS in association with growth inhibition of NSCLC cells. (a) Structural modeling of KRA-533 in the GTP/GDP-binding
pocket of KRAS protein. (b) Various NSCLC cells with or without KRAS mutation were treated with KRA-533 (10 μM) for 48 h. KRAS-GTP (active form of
KRAS) was pulled down by Raf-1-RBD, followed by Western blot using KRAS antibody. (c) and (d) Various NSCLC cells were treated with KRA-533
(10 μM) for 10 days, followed by colony formation assay with quantification. Error bars represent ± SD. *P < 0.05, **P < 0.01, by 2-tailed t test

computational modeling analysis reveals that KRA-533 is
associated with 15 amino acids (Leu120, Asn85, Phe28,
Glu31, Asp30, Ala18, Pro34, Val29, Asp33, Lys117, Val14,
Lys16, Asp57, Ser17 and Tyr32) in the GDP/GTP binding
pocket. Among KRA-533-associated amino acids in the
KRAS protein, two hydrogen bonds are predicted with
residues Ser17 and Lys117. We mutated these two sites to
Ala individually or simultaneously, leading to generation of
S17A, K117A and AA (i.e. S17A/K117A) KRAS mutants.
Thermal shift assay indicates that KRA-533 could bind to
recombinant WT and S17A KRAS proteins but failed to
bind K117A and AA mutant KRAS proteins (Fig. 3A). Intriguingly, KRA-533 directly activated WT and S17A but
not K117A mutant KRAS in a cell-free GDP-GTP exchange system (Fig. 3B). To further test this intracellularly,
GFP-tagged WT, S17A, K117A and AA KRAS mutants

were exogenously transfected into A549 cells. Then, cells
were treated with KRA-533 for 48 h, followed by Raf-1RBD beads pull-down. Activities of exogenous GFP-tagged
WT and KRAS mutants were analyzed by Western blot
using GFP antibody. Consistently, KRA-533 activated
exogenous WT and S17A but not K117A KRAS mutant in
A549 cells (Fig. 3C). These findings suggest that the Lys117
hydrogen-bond site is required for KRA-533 to bind or
activate KRAS.
KRA-533-induced KRAS activation promotes apoptosis
and autophagic cell death in human lung cancer cells

It has recently been reported that activated KRAS can trigger cell death via apoptosis and autophagy-associated cell
death in cancer cells [1, 23–25]. To test whether KRA-533activated KRAS promotes apoptosis and autophagic cell
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Fig. 2 KRA-533 directly binds to and activates KRAS in an in vitro cell-free system. (a) Thermal shift melting curve of purified KRAS proteins (WT,
G12C, G12D or G13D) incubated with increasing concentrations of KRA-533. Melting temperature (Tm) values of DMSO Ctrl and 15 μM of KRA-533
are shown. *P < 0.05 by 2-tailed t test. (b) 600 nM Purified KRAS protein (WT, G12C, G12D or G13D) was incubated with 11 μM [γ-35S] GTPγS, purified
GFP (RASGRP1, 180 nM) and GAP (RASA1, 180 nM) at 25 °C in the presence or absence of increasing concentrations of KRA-533. The radioactivity
remaining on the protein after intensive washing was quantified by liquid scintillation. Error bars represent ± SD. **P < 0.01 by 2-tailed t test

death, A549, H157, Calu-1 and H292 cells were treated with
increasing concentrations of KRA-533 for 48 h, followed by
analysis of KRAS activity, apoptosis and autophagy.
KRA-533 enhanced KRAS activity in a dose-dependent
manner, which was associated increased levels of pERK, ratio of active caspase 3/procaspase 3 and PARP cleavage,
leading to apoptotic cell death determined by FACS analysis
of Annexin V/PI staining (Fig. 4A and B), measurement of
caspase 3 activity using a Caspase 3 Colorimetric Assay Kit
and mitochondrial membrane potential using JC-1 staining
(Additional file 2: Figure S2). We also measured autophagy
by analysis of LC3-I/LC3-II and p62 following treatment of
cells with KRA-533. It is well known that p62 is an autophagy receptor or substrate that can be degraded by autophagy
[52]. In addition to LC3-II, we analyzed p62 as another autophagy marker. Intriguingly, KRA-533 induced a
dose-dependent increase of LC3-II and a dose-dependent
decrease of p62 in A549, H157, Calu-1 cells and H292 (Fig.
4A). To further quantify the level of autophagy, a GFP-LC3
construct was used to indicate autophagosomes as previously described [49, 53]. After treatment with KRA-533,
GFP-LC3 redistributed from a diffuse staining pattern in the
cytoplasm and nucleus to a cytoplasmic punctate structure
that specifically labels pre-autophagosomal and autophagosomal membranes (i.e. GFP-LC3 vac cells, Additional file 3:

Figure S3). Intriguingly, KRA-533 enhanced the percentage
of GFP-LC3vac cells in a dose-dependent manner (Fig. 4C).
These findings indicate that, in addition to apoptosis,
KRA-533 can also induce autophagic cell death. Importantly, A549, H157 and Calu-1 cells with KRAS mutation
were significantly more sensitive than H292 cells without
KRAS mutation to KRA-533-stimulated KRAS activation,
induction of apoptosis and autophagy (Fig. 4), suggesting
that KRA-533 may be relatively selective for cancer cells
bearing KRAS mutation(s).
To assess whether the autophagy inhibitor regulates
KRA-533-induced autophagy formation, A549 and H157
cells were treated with KRA-533 in the absence or presence of autophagy inhibitor chloroquine for 48 h, followed
by Western blot analysis of the autophagy marker p62.
KRA-533 induced autophagy with deceased p62 level via
degradation. The autophagy inhibitor chloroquine restored p62 expression by blocking KRA-533-induced p62
degradation. These findings indicate that autophagy inhibitor chloroquine has ability to block KRA-533-induced
autophagy (Additional file 4: Figure S4).
To determine whether autophagy plays a role in apoptosis induced by KRA-533, we measured apoptosis by
FACS analysis of Annexin V/PI staining following treatments of A549 and H157 with KRA533 alone or in
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Fig. 3 K117 site is essential for KRA-533 to bind and activate KRAS. (a) Thermal shift melting curve of purified KRAS protein (WT, S17A, K117A, or
S17A/K117A (AA)) incubated with increasing concentrations of KRA-533. Melting temperature (Tm) values of DMSO control and 15 μM KRA-533
are shown. *P < 0.05, no significance → NS, by 2-tailed t test. (b) 600 nM purified KRAS protein (WT, S17A, K117A or AA) was incubated with 11 μM [γ35S] GTPγS, purified GFP (RASGRP1, 180 nM) and GAP (RASA1, 180 nM) at 25 °C in the presence or absence of 15 μM KRA-533. The radioactivity
remaining on the protein after intensive washing was quantified by liquid scintillation. Error bars represent ± SD. *P < 0.05 by 2-tailed t test. (c) A549
cells were transfected with GFP-tagged KRAS WT, S17A, K117A or AA, followed by treatment with KRA-533 (15 μM) for 48 h. KRAS·GTP (active KRAS)
was pulled down by Raf-1-RBD. The GFP-tagged exogenous KRAS-GTP (GFP-KRAS-GTP) was analyzed by Western blot using anti-GFP antibody

combination with autophagy inhibitor 3-MA for 48 h. Results show that the autophagy inhibitor 3-MA enhanced
KRA-533-induced apoptosis (Additional file 5: Figure S5).
To further test whether KRAS is a required target for
KRA-533 to induce apoptotic and autophagic cell death,
G12S mutant KRAS was depleted using KRAS shRNA
from A549 cells, followed by treatment with KRA-533
(15 μM) for 48 h. Knockdown of mutant KRAS significantly reduced cell sensitivity to the induction of apoptotic and autophagic cell death by KRA-533 (Additional
file 6: Figure S6). These findings suggest that KRAS may
be an essential target for KRA-533 against lung cancer
via apoptotic and autophagic cell death pathways.
KRA-533 suppresses mutant KRAS lung cancer in
xenograft models

To define the appropriate doses of KRA-533 for in vivo experimentation, we first determined standard single-dose
maximum tolerated dose (MTD) as previously described

[49]. Nu/Nu nude mice were treated with a single dose of
150, 300 or 400 mg/kg i.p., followed by toxicity observations. Treatment of mice with a single dose of 150 or 300
mg/kg i.p. did not cause weight loss or other toxicities, including hematologic disorders, or liver and kidney function
abnormalities (Additional file 7: Figure S7). However, a single dose of 400 mg/kg resulted in death of mice in 8 days.
Alanine transaminase (ALT), aspartate transaminase (AST)
and blood urea nitrogen (BUN) were significantly elevated
(Additional file 7: Figure S7). Based on these findings, mice
might die mainly from liver and kidney damage at a single
400 mg/kg dose. Thus, the single dose MTD of KRA-533
ranges from 300 to 400 mg/kg. 10% of single-dose MTD
can usually be considered the maximum therapeutic dose
(~ 30–40 mg/kg) for continuous treatment. We therefore
considered doses between 10 and 30 mg/kg/day to be
relatively safe.
To test the potency of KRA-533 in vivo, lung cancer
xenografts derived from A549 cells bearing KRAS
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Fig. 4 (See legend on next page.)
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(See figure on previous page.)
Fig. 4 KRA-533 induces KRAS activation leading to apoptotic and autophagic cell death in human lung cancer cells. (a) and (b), A549, H157, Calu1 and H292 cells were treated with increasing concentrations (0, 5, 10, 15 μM) of KRA-533 for 48 h. “0” means DMSO vehicle control. KRAS-GTP
(active form of KRAS) was pulled down by Raf-1-RBD, followed by Western blot using KRAS antibody. Expression levels of KRAS, pERK, active
caspase 3, PARP cleavage, Beclin1, LC3-I and LC3-II in total lysate were analyzed by Western blot. Apoptosis was determined by analyzing
Annexin-V/PI binding by FACS. Data represent mean ± SD, *P < 0.05, **P < 0.01, by 2-tailed t test. (c) GFP-LC3 plasmids were transfected into A549,
H157, Calu-1 and H292 cells. After 24 h, cells were treated with KRA-533 for 48 h. The percentages of LC3-GFP-transfected cells bearing LC3-GFP
aggregates (LC3-FGPvac) were quantified as shown. Data represent mean ± SD, **P < 0.01, by 2-tailed t test

mutation (G12S) were treated with increasing doses (0,
7.5, 15, and 30 mg/kg/day) of KRA-533 i.p. for 28 days.
KRA-533 suppressed tumor growth in a dose-dependent
manner in lung cancer mutant KRAS xenografts (Fig. 5A).
To assess whether KRA-533 induced suppression of
tumor growth via apoptosis and autophagy in vivo, representative samples from harvested tumor tissues were analyzed by immunohistochemistry (IHC) for active caspase3 or LC3-II as described [45, 46]. Indeed, KRA-533 induced apoptosis and autophagy in tumor tissues in a
dose-dependent manner (Fig. 5B). Raf-1-RBD pull-down
experiments for KRAS activity were also carried out using
total cell lysates isolated from tumor tissues. Treatment of
mice with KRA-533 resulted in accumulation of active
KRAS in tumor tissues in association with increased apoptosis and autophagy (Fig. 5C), suggesting KRA-533mediated tumor suppression may occur through induction of apoptosis and autophagic cell death.
Treatment was well tolerated without significant toxicity within effective dose range (7.5 ~ 30 mg/kg/d).
There was no weight loss (Fig. 6A). Tests of blood cells
(WBC, RBC and PLT) for bone marrow, BUN for kidney
and ALT/AST for liver functions were in the normal
range (Fig. 6B). Histopathology of harvested normal tissues (brain, heart, lung, liver, spleen, kidney and intestine) revealed no evidence of normal tissue toxicities
after treatment with doses of 7.5~30 mg/kg/day (Fig.
6C). These findings suggest that doses between 7.5 and
30 mg/kg provide the optimal therapeutic index for
KRA-533 for in vivo studies.

KRA-533 potently inhibits tumor growth and prolongs
survival of mice with genetically engineered G12D
mutant KRAS-driven lung cancer

KRAS mutations are common genetic alterations in
NSCLC and contribute to the resistance of lung cancer
to conventional therapy [11, 12, 18]. To test the potency
of KRA-533 in mutant KRAS-driven lung cancer, we
generated lox-stop-lox (LSL)-KRASG12D mice as previously described [47, 48, 54, 55]. By engineering LoxP
DNA elements into the mouse genome that surround a
synthetic ‘stop’ element (lox-stop-lox) inserted in front
of mutant KRAS G12D, we can ‘turn-on’ mutant KRAS
G12D with delivery of Cre recombinase [56]. To control

the expression of KRAS G12D, a LSL cassette was engineered into the first intron of the KRAS gene. The LSL
cassette consists of transcriptional and translational stop
elements flanked by LoxP sites that prevent the expression of the mutant allele until the stop elements are removed by the activity of Cre recombinase [54, 55]. To
produce KRAS G12D mutant-driven lung cancer, alleles
were induced in mouse lung using intranasal administration of a lentiviral Cre recombinase. Primary lung tumors developed around 12 weeks post-inoculation. To
assess whether KRA-533 has antitumor activity against
G12D mutant KRAS-driven lung cancer in genetically
engineered mouse models, KRA-533 (20 mg/kg/d) or vehicle control was administered i.p. starting at 10 weeks
post AdeCre delivery as previously suggested [48]. After
treatment for 3 months, mice were euthanized for analysis of tumor burden as previously described [46, 48].
Treatment of KRAS G12D mice with KRA-533 for four
months resulted in significant reduction of tumor burden and multiplicity in the lung (Fig. 7A and B). Importantly, KRA-533 prolonged survival of KRAS G12D mice
compared with the control group (Fig. 7C). There were
3 deaths out of 8 mice in the control group versus 1
death out of 8 mice in the KRA-533 treatment group (p
< 0.01) in four months before euthanization. Slight
weight loss but no significant normal tissue toxicities
were observed in mice (Additional file 8: Figure S8).
Around half of KRAS-mutant lung cancer patients
also carry LKB1 mutations, therefore, it will be important to test whether KRA-533 is also effective for the
treatment of KRAS-mutant lung cancers with LKB1
mutation or loss. LSL-KRASG12D LKB1fl/fl (KL) mice
were generated by intercrossing B6.129S4-Krastm3Tyj/J
(KRASG12D) and FVB; 129S6-Stk11tm1Rdp/Nci (LKB1)
strains two generations and genotyped to confirm
homozygosity for the LKB1 allele. These mice contain a
KRASG12D LSL knock-in allele and a floxed allele of
LKB1 (LKB1fl/fl) [47, 48]. KRA-533 (20 mg/kg/d) or vehicle control was administered i.p. starting at 6 weeks
post AdeCre delivery as previously suggested [46, 48].
After treatment for 8 weeks, mice were euthanized and
lung tumors were analyzed as described above. Results
reveal that KRA-533 also significantly suppressed
tumor growth and prolonged survival of KL mice (Additional file 9: Figure S9).
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Fig. 5 KRA-533 potently suppresses tumor growth in KRAS mutant lung cancer xenografts. (a) Nu/Nu nude mice with A549 xenografts bearing
mutant KRAS were treated with increasing doses of KRA-533 (0, 7.5, 15, and 30 mg/kg/d) for 28 days (n = 6). Tumor volume was measured once
every 2 days (left panel). Tumor volumes of 6 individual mice in each group were compared on day 28 (right panel). After 28 days, the mice were
sacrificed, and the tumors were removed and analyzed. Data represent mean ± SD, n = 6 per group. *P < 0.05, **P < 0.01, by 2-tailed t test. (b)
Active caspase-3, LC3-II and p-ERK were analyzed by IHC staining in tumor tissues at the end of experiments and quantified. Data represent
mean ± SD, n = 6 per group. *P < 0.05, **P < 0.01, by 2-tailed t test. (b) KRAS-GTP (active form of KRAS) was pulled down by Raf-1-RBD from tumor
tissue lysates, followed by Western blot using KRAS antibody. Expression levels of active caspase-3, cleaved PARP, Beclin-1 and LC3-II in tumor
tissues were analyzed by Western blot
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Fig. 6 Toxicity of KRA-533 in vivo. (a), (b) and (c) Body weight, blood analysis and H&E histology of various organs from mice bearing A549
xenografts after treatment with various doses of KRA-533 for 28 days

Discussion
Small-molecule drugs act by binding to proteins; those
proteins that harbor sites amenable to small molecule
binding are termed “druggable” [6, 57]. Despite more
than three decades of intensive effort, no effective
pharmacologically direct inhibitors of the RAS oncoproteins have reached the clinic, prompting the widely held
perception that RAS proteins are ‘undruggable’ [5]. Creation of therapeutic agents that directly inhibit the oncogenic effects of RAS proteins has been challenging [5].
Recently, direct KRAS G12C specific inhibitors have
been discovered, which irreversibly bind to a common
oncogenic mutant, KRAS (G12C) and allosterically control GTP affinity and effector interactions [38]. Based on

this finding, a more potent compound, ARS-853, has
been developed as an allele-specific inhibitor to selectively target and inactivate mutant KRAS G12C [58, 59].
ARS-853 binds to the switch II pocket of GDP-bound
KRAS-G12C, and leads to a generally inactive state of
KRAS. KRAS-G12C is able to cycle between GDP- and
GTP-bound states while ARS-853 inhibits this cycling.
KRAS G12C is unable to achieve the GTP-bound state
once bound by ARS-853 [58]. ARS-853 potently suppresses the growth of cancer cells bearing G12C mutant
KRAS, while cancer cells that express non-G12C mutants (i.e. G12D, G12S, G12 V, G13D, Q61K, etc.) are resistant to ARS-853 [58]. In addition to ARS-853, a
small-molecule pan-RAS inhibitor (compound 3144),
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Fig. 7 KRA-533 inhibits mutant KRASG12D driven lung cancer growth in genetically engineered mouse model. (a) After administration of
adenovirus Cre recombinase in KRASG12D mice for 10 weeks, mice were treated with KRA-533 (20 mg/kg/d) for four months (n = 8 each group).
H&E images from control or treatment group are shown. (b) Tumor numbers were counted under the microscope and tumor area was quantified
using Openlab modular imaging software. Data represent mean ± SD, n = 8 per group. **P < 0.01, by 2-tailed t test. (c) Survival of mice was
calculated up to four months before euthanization in the control group versus the KRA-533 treatment group. Data represent mean ± SD, n = 8
per group. **P < 0.01, by 2-tailed t test

was recently discovered by targeting multiple adjacent
sites on KRAS G12D protein near D38, A59 and Y32
sites [6]. Compound 3144 can prevent effector protein
binding and causes tumor growth inhibition in animal
models of RAS dependent cancers [6].
RAS has opposing functions in cell proliferation/survival
versus cell death pathways [1, 23–25]. Here we used the
GTP/GDP-binding pocket of KRAS as a docking site to
screen the NCI library of small molecules using the
UCSF-DOCK program suite. KRA-533 was identified as a
lead compound that targets the GTP/GDP-binding pocket
in KRAS protein. KRA-533 potently enhances intracellular
KRAS activities to various degrees in a series of human
NSCLC cell lines in association with various degrees of
growth inhibition. Intriguingly, lung cancer cell lines

bearing KRAS mutation are more sensitive to KRA-533
than those without KRAS mutation, indicating KRA-533
may be relatively selective for mutant KRAS lung cancer
cells. KRA-533 not only directly binds to WT KRAS
protein but also KRAS mutants, including G12C, G12D
and G13D. Although KRAS mutants have higher levels of
activities than WT KRAS before KRA-533 treatment,
KRA-533 induces a dose-dependent increase in activity of
WT and mutant KRAS in cell-free GDP-GTP exchange
assay and in lung cancer cells. Compared to WT KRAS,
the G12C, G12D and G13D KRAS mutants become hyperactive following KRA-533 treatment. It has been reported
that glucose withdrawal or glucose-mediated hyperactivation of RAS is able to trigger apoptosis [26, 28]. Hyperactivation of RAS can also trigger autophagy-associated cell
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death [1]. Here we found that KRA-533-induced hyperactivation of mutant KRAS led to apoptosis and autophagic cell
death in mutant KRAS lung cancer cell lines (i.e. A549,
H157 and Calu-1). In contrast, the moderate level of WT
KRAS activation induced by KRA-533 caused significantly
less apoptosis and autophagic cell death in a lung cancer
cell line without KRAS mutation (i.e. H292). Therefore,
there may be a threshold of KRAS activity in cells to dictate
pathway choice between survival and death. Based our
findings and previous reports, we propose that KRAS activity at or below the threshold may promote cell survival and
proliferation while KRAS activity beyond the threshold (i.e.
hyperactivation or super-activity) may promote cell death.
KRA-533 may change the nature of KRAS signaling from
pro-survival to pro-death by stimulating active mutant
KRAS to a super-active status that is beyond the activity
threshold.
Our data indicate that KRA-533 not only binds KRAS
but also directly activates its activity. Structural modeling
analysis by computational programming reveals that
KRA-533 is associated with 15 amino acids in the GDP/
GTP binding pocket, including the hydrogen-bond predicted with residue K117. Mutation of K117 to Ala resulted
in KRAS loss of KRA-533 binding capacity. KRA-533 failed
to activate K117A mutant KRAS. These findings indicate
that, in addition to GTP binding [60], the K117 site is also
critical for KRA-533 to bind to and/or activate KRAS. Intriguingly, a mutation of K117 in KRAS (K117 N) has been
found in cancer patients [21, 22], indicating that K117
should be an important site in KRAS for regulation of its
activity.
KRA-533 exhibited potent antitumor activity against
mutant KRAS lung cancer via induction of KRAS hyperactivation, apoptosis and autophagic cell death in NSCLC
xenografts. Importantly, the dose range between 10 and
30 mg/kg/day was effective without significant normal tissue toxicity in murine lung cancer models. Genetically
engineered mice are the most sophisticated animal models
of human cancer, which closely recapitulate the pathophysiological process of human malignancies in genetically precisely defined systems [56]. Therefore, the potency
of KRA-533 was evaluated in genetically engineered
LSL-KRASG12D and LSL-KRASG12D LKB1fl/fl (KL) mice.
Importantly, KRA-533 significantly reduces tumor burden
in the lungs of both LSL-KRASG12D and KL mice, leading
to prolonged survival compared to the untreated control
group, suggesting that KRA-533 has potential to improve
the prognosis of mutant KRAS driven lung cancer.

Conclusion
We have discovered KRA-533 as a new class of KRAS
agonist that selectively targets the GTP/GDP binding
pocket. The binding of KRA-533 with KRAS promotes
accumulation of GTP-KRAS probably by prevention of
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cleavage from GTP into GDP. KRA-553-induced hyperactivation of mutant KRAS facilitates apoptotic and autophagic cell death in mutant KRAS lung cancer cells.
KRA-533 also displays potent efficacy against tumor
growth in mutant KRAS xenografts and genetically engineered mutant KRAS driven lung cancer. Development
of this KRAS agonist may offer an effective approach for
the treatment of mutant KRAS lung cancer.

Additional files
Additional file 1: Figure S1. KRA-533 inhibits proliferation of NSCLC
cells. (A) A549, H157, Calu-1 and H292 cells were treated with increasing
concentrations of KRA-533, followed by analysis of cell proliferation using
MTS Cell Proliferation Colorimetric Assay Kit. (B) IC50 values of KRA533
based on cell proliferation data from (A). (JPG 700 kb)
Additional file 2: Figure S2. KRA-533 induces caspase 3 activation and
reduces mitochondrial membrane potential in NSCLC cells. (A) and (B)
A549, H157, Calu-1 and H292 cells were treated with increasing concentrations of KRA-533, followed by analysis of caspase 3 activity using Caspase 3 Colorimetric Assay Kit (A) and measurement of mitochondrial
membrane potential by JC-1 staining (B). Data represent mean ± SD, *P <
0.05, **P < 0.01, by 2-tailed t test. (JPG 2498 kb)
Additional file 3: Figure S3. KRA-533 induces autophagy formation in
NSCLC cells. A549, H157, Calu-1 and H292 cells were transfected with
GFP-LC3. After 24 h, cells were treated with KRA-533 for 48 h. Autophagic
vacuoles in the representative cells from various treatments were shown.
Scale bar represents 20 μm. (JPG 354 kb)
Additional file 4: Figure S4. The autophagy inhibitor chloroquine
blocks KRA-533-induced autophagy in NSCLC cells. A549 and H157 cells
were treated with KRA-533 (10 μM) in the absence or presence of autophagy inhibitor chloroquine (10 μM) for 48 h, followed by Western blot
analysis of the autophagy marker p62. (JPG 187 kb)
Additional file 5: Figure S5. The autophagy inhibitor 3-methyladenine
(3-MA) enhanced KRA-533-induced apoptosis of NSCLC cells. A549 and
H159 cells were treated with KRA-533 (10 μM) in the absence or presence
of 3-MA for 48 h, followed by FACS analysis of Annexin V/PI staining for
apoptosis. Data represent mean ± SD, *P < 0.05, by 2-tailed t test. (JPG 362
kb)
Additional file 6: Figure S6. Silencing of mutant KRAS reduced
sensitivity of cells to KRA-533. (A) KRAS shRNA plasmids were transfected
into A549 cells that contain KRAS mutation, followed by Western blot
using KRAS antibody. (B) A549 cells and mutant KRAS silenced A549 cells
were treated with KRA-533 (15 μM) for 48 h. Apoptotic cells were detected by Annexin V /PI binding and analyzed by FACS. Data represent
mean ± SD, **P < 0.01, by 2-tailed t test. (C) GFP-LC3 constructs and KRAS
shRNA plasmids were co-transfected into A549 cells, followed by treatment with KRA-533 for 48 h. Autophagic cells (GFP-LC3 positive cells)
were visualized by Axioplan Zeiss microscope and quantified. Data represent mean ± SD, **P < 0.01, by 2-tailed t test. (JPG 653 kb)
Additional file 7: Figure S7. Determination of single dose maximum
tolerated dose (MTD). (A) Nu/Nu nude mice were treated with single
dose (i.e. 0, 150 mg/kg, 300 mg/kg or 400 mg/kg) KRA-533 via i.p. (n = 6
mice per group). After treatment, the body weight of mice was measured
once every other day for 2 weeks. (B) Blood analysis of mice after treatment with single dose(s) of KRA-533. (C) H&E histology of various organs
from mice after treatment with single dose(s) of KRA-533. (JPG 1446 kb)
Additional file 8: Figure S8. Toxicity of KRA-533 in genetically engineered LSL-KRAS G12D mice. (A), (B) and (C), Body weight, blood analysis
and H&E histology of various organs from mice bearing A549 xenografts
after treatment with KRA-533 (20 mg/kg/d) for 4 months. (JPG 2133 kb)
Additional file 9: Figure S9. Potency of KRA-533 in genetically engineered LSL-KRASG12D LKB1fl/fl (KL) mice. (A) and (B) After administration of
adenovirus Cre recombinase in KL mice for 6 weeks, mice were treated
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with KRA-533 (20 mg/kg/d) for 8 weeks (n = 6 each group). Three representative brightfield images of mouse lungs and H&E images from control or KRA-533 treatment group are shown. (C) Tumor numbers were
counted under the microscope and tumor area was quantified using
Openlab modular imaging software. Data represent the mean ± SD, n = 6
per group. **P < 0.01, by 2-tailed t test. (D) Survival of mice was calculated
up to 8 weeks before euthanization in the control group versus the KRA533 treatment group. Data represent mean ± SD, n = 6 per group. **P <
0.01, by 2-tailed t test. (JPG 3111 kb)

Abbreviations
ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; BUN: Blood
urea nitrogen; KRA-533: KRAS agonist-533; KRAS: Kirsten rat sarcoma viral
oncogene; MTD: Maximum tolerated dose; NSCLC: Non-small cell lung
cancer; SRB: Sulforhodamine B
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